Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?: https://g.foolcdn.com/editorial/images/731652/gettyimages-88689535.jpg
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?

Axsome Therapeutics (NASDAQ: AXSM) stood out last year. The biotech began selling its first two products: Sunosi, a sleep disorder drug it acquired from Jazz Pharmaceuticals; and Auvelity, an

Why CRISPR Therapeutics Stock Is on Fire Today: https://g.foolcdn.com/editorial/images/731718/pig-taking-flight.jpg
Why CRISPR Therapeutics Stock Is on Fire Today

Shares of the developmental gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) were up by 12.4% on sky-high volume as of 1:46 p.m. ET Tuesday afternoon. The big gain came in response to the bio

Why Catalent Stock Was a Disaster Today: https://g.foolcdn.com/editorial/images/731563/stethescope-atop-us-currency-and-coins.jpg
Why Catalent Stock Was a Disaster Today

The struggles of contract drugmaker Catalent (NYSE: CTLT) continued on Monday, leading to a big sell-off in the company's stock. Investors were heavily discouraged by their company's latest update

Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Axsome Therapeutics (AXSM) Q1 2023 Earnings Call Transcript

Image source: The Motley Fool.

Axsome Therapeutics (NASDAQ: AXSM)Q1 2023 Earnings CallMay 08, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Why Wall Street Took a Hit From These 2 NYSE Stocks: https://g.foolcdn.com/editorial/images/731485/chickens-gettyimages-576736468.jpg
Why Wall Street Took a Hit From These 2 NYSE Stocks

Monday was a relatively quiet day on Wall Street, with most major benchmarks seeing modest losses at midday. With key inflation and other economic data coming in the near future, investors are

1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now: https://g.foolcdn.com/editorial/images/729512/businessmen-and-doctors-working-on-touchpad-in-a-hospital.jpg
1 Relatively Safe Dividend Growth Stock to Buy Hand Over Fist Right Now

If you can buy high-quality dividend stocks when other investors sour on them, you can plant the seeds for robust returns in the future. And that's exactly why it might be worth buying shares of

Looking for Steady, Passive Income? Buy AbbVie Stock: https://g.foolcdn.com/editorial/images/730634/a-doctor-and-patient-talk-to-each-other-during-an-appointment.jpg
Looking for Steady, Passive Income? Buy AbbVie Stock

Dividend growth investing revolves around selecting only the most reliable businesses for your portfolio. This can be measured by consecutive years of dividend growth.

With 51 consecutive years of

Better Gene Sequencing Stock: Illumina vs. Bionano Genomics: https://g.foolcdn.com/editorial/images/729509/two-scientists-work-at-lab-bench-with-scope.jpg
Better Gene Sequencing Stock: Illumina vs. Bionano Genomics

Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the

Why Illumina Fell 11.6% in April: https://g.foolcdn.com/editorial/images/731339/genetic-sequencing.jpg
Why Illumina Fell 11.6% in April

Shares of Illumina (NASDAQ: ILMN) fell by 11.6% in April, according to data provided by S&P Global Market Intelligence.

The fall means that shares of the gene-sequencing company have only inched up

3 Great Income Stocks That Retirees Should Love: https://g.foolcdn.com/editorial/images/731008/happy-older-couple-retirement-wealth-invest.jpg
3 Great Income Stocks That Retirees Should Love

Most Americans don't have to wait until they're retired to know that Social Security benefits won't be enough to maintain their current lifestyle. If they pay any attention to retirement planning

Cigna Group (CI) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Cigna Group (CI) Q1 2023 Earnings Call Transcript

Image source: The Motley Fool.

Cigna Group (NYSE: CI)Q1 2023 Earnings CallMay 05, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

2 Magnificent Dividend Stocks to Buy Before the Next Recession: https://g.foolcdn.com/editorial/images/730574/elderly-person-sitting-on-a-bed.jpg
2 Magnificent Dividend Stocks to Buy Before the Next Recession

Fears of a coming recession are probably about as high right now as they have been over the past year. That's because the U.S. Federal Reserve recently predicted an economic downturn would descend

Should You Buy Novocure Stock Right Now?: https://g.foolcdn.com/editorial/images/730947/novocure-person-with-ttfields-on-head.jpg
Should You Buy Novocure Stock Right Now?

Going, going, gone? That could be the question that Novocure (NASDAQ: NVCR) investors are asking these days. Shares of the oncology company plunged 56% in 2021. The stock slid 2% lower last year

Why Karyopharm Therapeutics Shares Slumped Thursday: https://g.foolcdn.com/editorial/images/731087/using-a-stethoscope-listen-to-the-heartbeat-of-patient-1.jpg
Why Karyopharm Therapeutics Shares Slumped Thursday

Shares of Karyopharm Therapeutics (NASDAQ: KPTI) were down more than 26% Thursday afternoon after the biotech company released first-quarter earnings and updated its guidance. The stock fell to its

Vaccine Sales Are Falling. Should You Still Buy Pfizer?: https://g.foolcdn.com/editorial/images/730746/gettyimages-1252566534.jpg
Vaccine Sales Are Falling. Should You Still Buy Pfizer?

Pfizer (NYSE:PFE) confirmed this week what everyone has been expecting. COVID-19 vaccine sales are falling drastically. The company reported a 77% drop in Comirnaty sales in the first quarter

Why Regeneron Pharmaceuticals Stock Is Tanking Today: https://g.foolcdn.com/editorial/images/730998/crashing-arrow.jpg
Why Regeneron Pharmaceuticals Stock Is Tanking Today

Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today. Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of

Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call Transcript

Image source: The Motley Fool.

Karyopharm Therapeutics (NASDAQ: KPTI)Q1 2023 Earnings CallMay 04, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Zoetis (ZTS) Q1 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Zoetis (ZTS) Q1 2023 Earnings Call Transcript

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q1 2023 Earnings CallMay 04, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

2 High-Yielding Dividend Stocks Analysts Expect Will Rise by at Least 50%: https://g.foolcdn.com/editorial/images/730233/an-advisor-explaining-a-chart-to-clients.jpg
2 High-Yielding Dividend Stocks Analysts Expect Will Rise by at Least 50%

Investors often gloss over dividend stocks, assuming that they offer nothing more than a recurring payout. But there are a couple of stocks that analysts are bullish about and that they believe

2 Potentially Explosive Stocks to Buy in May: https://g.foolcdn.com/editorial/images/730672/dna-genetic-sequencing-biotech-1.jpg
2 Potentially Explosive Stocks to Buy in May

Stag Industrial (NYSE: STAG) and Vertex Pharmaceuticals (NASDAQ: VRTX) are off to a good start this year, and some industry tailwinds look to really boost shares in the coming years. Stag, which

3 Top Healthcare Stocks to Buy in May: https://g.foolcdn.com/editorial/images/730742/scientists-high-five-smile.jpg
3 Top Healthcare Stocks to Buy in May

Healthcare stocks always make a great addition to long-term portfolios. They offer you the potential to benefit from steady earnings growth over time. After all, regardless of the economic

Why Amgen Stock Was Sickly Today: https://g.foolcdn.com/editorial/images/730881/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg
Why Amgen Stock Was Sickly Today

Investors are often encouraged when one of their companies bulks up by acquiring a peer. But that sentiment can turn sour if the takeover target stumbles.

This was the impetus behind Amgen's

2 Things About AbbVie That Investors Are Ignoring: https://g.foolcdn.com/editorial/images/730557/gettyimages-1318178022.jpg
2 Things About AbbVie That Investors Are Ignoring

Investors were ready for declines in AbbVie's (NYSE: ABBV) blockbuster immunology drug Humira. The product now is facing competition in the U.S. So, seeing a 26% drop in Humira's U.S. first-quarter

Why Eli Lilly Stock Is Bolting Higher Today: https://g.foolcdn.com/editorial/images/730771/alzheimers.jpg
Why Eli Lilly Stock Is Bolting Higher Today

Shares of the Illinois-based drugmaker Eli Lilly (NYSE: LLY) were up by 6% on heavy volume as of 1:45 p.m. ET Wednesday.

What sparked this latest rally? Ahead of the opening bell, Lilly announced

Why ImmunoGen Stock Is Soaring Wednesday: https://g.foolcdn.com/editorial/images/730764/clovisnew.jpg
Why ImmunoGen Stock Is Soaring Wednesday

Shares of ImmunoGen (NASDAQ: IMGN) were up by 139% Wednesday morning after the company announced positive trial data concerning an ovarian cancer drug the company has in its pipeline. The biotech